

Synthesis and Vaccine Evaluation of the Tumor Associated Carbohydrate Antigen RM2 from Prostate Cancer

Hong-Yang Chuang, Chien-Tai Ren, Chung-An Chao, Chung-Yi Wu, SACHIN SHANKAR SHIVATARE, Ting-Jen R. Cheng, Chung-Yi Wu, and Chi-Huey Wong

J. Am. Chem. Soc., **Just Accepted Manuscript** • DOI: 10.1021/ja403609x • Publication Date (Web): 02 Jul 2013

Downloaded from <http://pubs.acs.org> on July 9, 2013

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3
4 **Synthesis and Vaccine Evaluation of the Tumor Associated**
5
6
7 **Carbohydrate Antigen RM2 from Prostate Cancer**
8

9 Hong-Yang Chuang^{†,‡}, Chien-Tai Ren[†], Chung-An Chao[†], Chung-Yi Wu[†], Sachin S
10
11 Shivatare^{†,§,‡}, Ting-Jen R. Cheng[†], Chung-Yi Wu^{†,*}, and Chi-Huey Wong^{†,‡,‡,*}
12
13

14
15 †. Genomics Research Center, Academia Sinica, 128 Academia Road, Section 2,
16
17
18 Nankang, Taipei 115, Taiwan.
19

20
21 ‡. Department of Chemistry, National Taiwan University, 1 Roosevelt Road, Section
22
23
24 4, Taipei, 106, Taiwan.
25

26
27 §. Chemical Biology and Molecular Biophysics, Taiwan International Graduate
28
29
30 Program, Academia Sinica, Taiwan.
31

32
33 ‡. Institute of Biochemical Sciences, National Taiwan University, 1 Roosevelt Road,
34
35
36 Section 4, Taipei, 106, Taiwan.
37

38
39 *To whom correspondence should be addressed: C-Y. Wu, Tel: +886-2-27871263,
40

41 Fax: +886-2-27898771, E-mail: cyiwu@gate.sinica.edu.tw or C.-H. Wong, Tel:

42
43
44 +886-2-27899400, Fax: +886-2-27853852, E-mail: chwong@gate.sinica.edu.tw (or
45
46
47 wong@scripps.edu).
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

We have successfully developed a [1+2+3] one-pot strategy to synthesize the RM2 antigen hexasaccharide that was proposed to be a prostate tumor antigen. The structure of the synthetic product was verified by NMR analysis and antibody binding assay using a glycan microarray. In addition, the synthetic antigen was conjugated to a mutated diphtheria toxin (DT, CRM197) with different copy numbers and adjuvant combination to form the vaccine candidates. After vaccination in mice, we used glycan microarrays to monitor their immune response, and the results indicated that when one molecule of DT was incorporated with 4.7 molecules of RM2 in average (DT-RM_{4.7}) and adjuvanted with the glycolipid C34 exhibited the strongest anti-RM2 IgG titer. Moreover, the induced mouse antibodies mediated effective complement-dependent cytotoxicity (CDC) against the prostate cancer cell line LNCap.

Introduction

An ideal target antigen for development of cancer vaccine should be specifically expressed on cancer cells and accessible to the immune system. Tumor associated carbohydrate antigens (TACAs) are not only most abundantly and sometimes aberrantly expressed on the surface of cancer cells but also absent or rarely expressed on normal cells.¹ Many TACAs have been characterized for specific types of cancer² and suggested for the development of tumor-specific vaccines.^{3,4} However, because carbohydrates generally display poor immunogenicity, a glycan vaccine conjugated with a carrier protein can stimulate the immune response. One example is the Globo H-KLH vaccine, which was first synthesized by Danishefsky and co-workers via the convergent glycal assembly strategy to Keyhole limpet hemocyanin (KLH)

1
2
3 conjugate.^{5,6} In the phase I clinical trial of Globo H-KLH,^{7,8} ~700 (Globo H) GH units
4 conjugated to one KLH protein was administered together with QS21 adjuvant. The
5 treatment appeared to be fairly well-tolerated and was capable of inducing a high titer
6 of IgM antibodies that participate in complement-mediated tumor cell lysis. Currently,
7 this vaccine is in phase III clinical trials in Taiwan and in phase II clinical trials in
8 USA, Korea, Hong-Kong and India. Moreover the similar synthetic approaches have
9 been utilized to synthesize other vaccines (e.g., fucosyl-GM1-KLH^{9,10} and Le^y-KLH¹¹)
10 against other types of cancer.
11
12
13
14
15
16
17
18
19
20
21
22

23 In this study, we focused on a novel TACA, the RM2 antigen (Fig. 1), a
24 glycosphingolipid (GSL) isolated and identified by Hakomari and colleagues from a
25 renal cell carcinoma cell line TOS-1 and prostate cancer cell lines LNCap and PC-3.¹²
26 It was immunocharacterized by the monoclonal antibody RM2 and, therefore, termed
27 the “RM2 antigen”. The RM2 antigen, β -1.4-GalNAc-disialyl-Lc, is highly expressed
28 on the prostate cancer cell surface as a glycolipid and possibly as a glycoprotein.¹³ In
29 addition, the RM2 antigen expression is closely associated with the prostate cancer
30 staging Gleason grading system, and is upregulated as the Gleason grade increases.¹⁴
31 Therefore, the RM2 antigen can also be developed as a new and novel marker for
32 prostate cancer. The structure of the RM2 antigen consists of a novel hybrid core with
33 the “ganglio-series” and the “disialyl lacto-series type 1 chain” groups (Fig. 1) and is
34 easily confused with the DSGG antigen, because (1) RM2 and DSGG are
35 indistinguishable on high performance thin-layer chromatography and (2) the renal
36 cell carcinoma expresses many types of disialogangliosides and other globo-series
37 monosialogangliosides, leading to varying proportions of globo-series and ganglio
38 /lacto-series antigens.¹⁵
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 On the other hand, this internal hexasaccharide RM2 without the GlcNAc residue is
5 identical to $\alpha(2,3)/\alpha(2,6)$ -disialyl lactotetraose (DSLc4), which was observed as a
6 colonic cancer-associated antigen by using a monoclonal antibody (FH9)¹⁶ for
7 siglec-7.¹⁷ Recently, Kiso and co-workers reported a systematic synthesis of DSLc4
8 via the α -stereoselective sialylation of O-6 and introduction of the sialyl- α -(2 \rightarrow
9 3)-D-galactose unit to the O-3 position of GlcNAc.¹⁸
10
11
12
13
14
15
16
17
18

19 To further verify the proposed structure of the RM2 antigen, we chemically
20 synthesized the proposed hexasaccharide **1** and evaluated its recognition by
21 monoclonal antibody RM2. To our best knowledge, the RM2 carbohydrate antigen
22 has not been synthesized; the introduction of two sialic acid units to the compact and
23 rigid 3,4 dibranched galactoside unit is very challenging, due to (1) the presence of
24 the C1 carboxyl group of sialic acids reduces the reactivity of the anomeric position;
25 and (2) the lack of C-3 participating group fails to direct the stereoselectivity and, at
26 the same time, readily promotes the undesired 2,3-elimination. Many approaches have
27 been developed to address these problems, including: (1) the design of different
28 leaving groups at the anomeric center¹⁹⁻²¹; (2) the installation of TFA²² or Troc²³ at the
29 *N*-5 position; (3) the 1,5- intramolecular lactamization²⁴; (4) the use of acetonitrile as
30 solvent in glycosylation²⁵; and (5) the installation of 5-*N*,4-*O*-carbonyl group
31 (oxazolidinone ring) in sialic acid as protecting group.²⁶ Recently, our group
32 incorporated the dibutyl phosphate as leaving group into the
33 *N*-acetyl-5-*N*,4-*O*-carbonyl-protected sialoside as a new sialyl donor to increase
34 α -selectivity and reaction yield.²⁷
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Besides the difficulty of sialylation, the development of a method for the
57 β -selective and efficient glycosylation of the galactosamine moiety at the 4-position
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of dibranched galactose is problematic owing to the steric hinderence of the adjacent sialyl moiety. Here, we describe the use of our sialyl phosphate as donor to enable an effective synthesis of the hexasaccharide of the proposed RM2 antigen using the [1+2+3] one-pot sequential strategy²⁸ with high yield and α -selectivity. The one-pot oligosaccharide synthesis strategy has been recognized as a powerful method to assemble complex oligosaccharides.²⁹ There are three general one-pot strategies for this purpose: (1) the chemoselective strategy,^{28,30,31} (2) the preactivation strategy,³² and (3) the orthogonal strategy.³³ Although the one-pot synthetic strategy is still needed to build the individual differentially protected building blocks, the major advantage of this method is that the purification of each coupling is not necessary. One just needs to purify the final products after the one-pot reaction. We also synthesized some of the truncated analogs of the proposed RM2 antigen in good yields and stereoselectivity. With these synthetic carbohydrates in hand, we used the RM2 antibody for binding analysis on a glycan array to confirm our synthetic structure. We then conjugated the synthetic RM2 antigen to the carrier protein CRM197 to form the vaccine candidate for vaccination in mice. Glycan arrays were used to monitor the titers of the induced antibody and specificity. We further evaluated the efficacy of the vaccines by CDC assay using the prostate cancer cell line LNCap.




Fig. 1. The structure of a RM2 carbohydrate hapten **1**. A: ganglio-series structure. B: disialyl lacto-series type 1 structure.

Results and discussion

Retrosynthesis. Two main problems in the synthesis of the target compound **1** are encountered: α -stereo- and regio-selective sialylation at *O*-6 of the GlcNAc residue and *O*-3 of the Gal residue; and β -selective glycosylation of GalNAc at the *O*-4 position of the sialyl- α -(2,3)-D-galactose unit.

After careful analysis of the structure of hexasaccharide **1**, we decided to approach the synthesis from a suitably protected hexasaccharide **2** (Fig. 2). The hydroxypentamine linker at the reducing end of the galactose residue was designed for immobilizing hexasaccharide **1** onto the NHS-coated slides or conjugating to a carrier protein to form a vaccine candidate. To use the step by step protocol for oligosaccharide synthesis, orthogonal protecting groups were required to provide potential acceptor sites for later glycosylation. Overall, the target hexasaccharide can be divided into three parts, monosaccharide **3**,³⁴ disaccharide **4**, and trisaccharide **5**, which are further divided into six monosaccharide building blocks **3**, **7**, **11**, **12**,²⁷ **15**, and **17**.




Fig. 2. Retrosynthetic analysis of the RM2 hapten.

Synthesis of GlcNAc building block 7. The synthesis of monosaccharide **7** can be achieved from the known 4,6-*O*-benzylidene acetal **6**³⁵ (Fig. 3). The *p*-methoxybenzylation of **6** was carried out by *p*-methoxybenzyl chloride (PMBCl) and sodium hydride (NaH) in DMF, followed by selective ring-opening of the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4,6-*O*-benzylidene group with dibutylboranetriflate (Bu₂BOTf) and borane-tetrahydrofuran complex (BH₃.THF). After sequential removal of the phthalimido group and Troc formation, the desired product **7** was produced in four steps in 24% yield.




Fig. 3. Synthesis of GlcNAc building block **7**. a. NaH, PMBCl, DMF, rt, 1 h; b. BH₃.THF, Bu₂BOTf, 0 °C, 2 h; c. Ethylenediamine, ethanol, 80 °C, 16 h; d. TrocCl, NaHCO₃, THF, rt, 16 h, overall yield 24%.

Synthesis of galactose building block 11. The known compound **8**³⁶ was acetylated by the standard acetylation procedure (Fig. 4), and the acetylated compound was glycosylated with the benzyl-5-hydroxypentylcarbamate in dichloromethane using NIS/TfOH as a promoter to afford **9** in 60% yield. Compound **9** was de-acetylated under the Zemplén condition; then, benzylation of the triol intermediate afforded **10** in 85% yield. The acetyl group was replaced by the benzyl group to increase the reactivity of the galactose building block, followed by selective removal of the PMB protecting group with DDQ to give **11** in 77% yield.




Fig. 4. Synthesis of Galactose building block **11**. a. Ac_2O , pyridine, rt, 12 h; b. NIS, cat. TfOH, benzyl 5-hydroxypentylcarbamate, CH_2Cl_2 , $-30\text{ }^\circ\text{C}$, 3 h, 60% (over two steps); c. NaOMe, MeOH, rt, 10 h; d. BnBr, NaH, rt, 2 h, 85% (over two steps); e. DDQ, $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$, rt, 2 h, 91%.

Synthesis of trisaccharide 5. Compounds **7**, **11**, and **12** were used as starting materials for the synthesis of trisaccharide building block **5** using an orthogonal one-pot synthetic strategy (Fig. 5). The one-pot synthetic operation was performed by sialyl phosphate donor **12** (1.5 eq.) and GlcNAc acceptor **7** (1.0 eq.) in the presence of TMSOTf at $-60\text{ }^\circ\text{C}$.

The second glycosylation between **7** and **11** was carried out by adding NIS (2.0 eq.) to the reaction solution at higher temperature ($-20\text{ }^\circ\text{C}$). Finally, removal of the PMB group by DDQ produced trisaccharide **5** as a single stereoisomer in 42% yield. The configuration of the trisaccharide **5** was examined by NMR spectrometry, and the new formed α -glycosidic bond was confirmed by coupling constant $^3J(\text{C}_1\text{-H}_{3\text{ax}}) = 6.0$ Hz.





Figure 5. Orthogonal one-pot synthesis of trisaccharide **5**. a. **7**, **12**, TMSOTf, MS 4Å, CH₂Cl₂ : CH₃CN = 1 : 2, -60 °C, 1 h; b. **11**, NIS, -20 °C, 2 h; c. DDQ, CH₂Cl₂, H₂O, rt, 12 h, overall yield 42%.

Synthesis of disaccharide 4. In order to synthesize the Neu5Ac α 2 \rightarrow 3Gal disaccharide with high α -stereoselectivity and yield, the thiophenyl group in the anomeric center of 5-*N*,4-*O*-carbonyl-protected thiosialoside **14**³⁷ was replaced by the dibutyl phosphate group at 0 °C under N-iodosuccinimide (NIS) and trifluoromethanesulfonic acid (TfOH) activation for 10 h to obtain **15** in 89% yield (α : β = 13:1). In addition, compound **16**³⁶ was efficiently converted to the corresponding 6-*O*-benzyl-4-hydroxy derivative **17** using triethylsilane (Et₃SiH) and trifluorosulfonic acid (TfOH) in a high yield with excellent region-selectivity. With the 3,4-dihydroxyl galactose acceptor **17** in hand, we first investigated the stereoselectivity of several sialyl phosphate donors including **15** with galactose acceptor **17** to produce Neu5Ac α 2 \rightarrow 3Gal disaccharide (Table S1), and the results

1
2
3
4 showed that the sialyl phosphate donor **15** had the excellent yields and
5
6 α -stereoselectivity. The glycosylation of **15** and **17** under the activation of TMSOTf in
7
8 CH_2Cl_2 at -78°C for 2 h gave Neu5Ac $\alpha 2\rightarrow 3\text{Gal}$ disaccharide **4** as a single isomer in
9
10 87% yield (Fig 6). The configuration of the disaccharide **4** was examined by NMR
11
12 spectrometry, and the new formed α -glycosidic bond was confirmed by coupling
13
14 constant $^3J(\text{C}_1\text{-H}_{3\text{ax}}) = 6.1\text{ Hz}$.
15



16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 **Fig. 6.** Synthesis of disaccharide **4**. a. NIS, TfOH, dibutylphosphate, MS 4Å, CH_2Cl_2 ,
42
43 0°C , 10 h, 89%; b. Et_3SiH , TfOH, MS 4Å, CH_2Cl_2 , -78°C , 1 h, 85%; c. TMSOTf,
44
45 CH_2Cl_2 , MS 4Å, -78°C , 2 h, 87%.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 7. Synthesis of hexasaccharide **2**. a. TMSOTf, MS 4Å, CH₂Cl₂, -50 °C, 2 h, 73%;
 b. NIS, TfOH, MS 4Å, CH₂Cl₂, 0 °C, 23 h, 62%.

Synthesis of compound 2. The preparation of the target hexasaccharide **2** was started from the TMSOTf-promoted coupling of the GalNAc donor **3**³⁴ with disaccharide **4**. After glycosylation, the fully protected trisaccharide compound **18** was isolated in 73% as a 6 to 1 mixture of rotamers (determined by ¹H NMR spectroscopic analysis of the crude reaction). Convergent synthesis of hexasaccharide **2** was achieved as a single stereoisomer in good yield (62%) by glycosylation of trisaccharide acceptor **5** with trisaccharide donor **18** in the NIS/TfOH promoting system at 0 °C for 23 h (Fig. 7). We further conducted an orthogonal one-pot [1+2+3] glycosylation and successfully synthesized the target hexasaccharide **2** (Fig. 8). Chemoselective glycosylation of the phosphate donor **3** with the thioglycoside **4** under the TBDMSOTf activation in CH₂Cl₂ at -50 °C provided trisaccharide **18**. Without isolation, the acceptor **5** and NIS were subsequently added to the reaction vessel at 0 °C and the reaction was finished in 23 h to afford the protected hexasaccharide **2** as a single stereoisomer in an overall yield of 32% based on **5**.




Fig. 8. One-pot synthesis of hexasaccharide **2**. a. **3**, **4**, TBDMSOTf, MS 4Å, CH₂Cl₂, -50 °C, 2 h; b. **5**, NIS, 0 °C, 22 h, 32% (over two steps) as a single stereoisomer.

Syntheses of truncated RM2 derivatives 20, 22, 24, and 26. Although RM2 antibody has been reported to recognize the RM2 antigen, its specificity for related carbohydrates is not well studied. To understand the specificity of RM2 antibody, we synthesized the RM2 antigen fragments **27**, **28**, **29**, **30**, and **31** to determine the specificity of monoclonal anti-RM2 antibody. The syntheses of the RM2 fragments **20**, **22**, **24**, and **26** followed the above method (Fig. 9). Donors **19**,³⁸ **21**,³⁸ or **23**²⁷ were coupled to acceptor **5** to give tetrasaccharide **20**, pentasaccharide **22**, or pentasaccharide **24**, respectively. In addition, treatment of the trisaccharide donor **18** and disaccharide acceptor **25** with NIS and a catalytic amount of TBDMSOTf at 0 °C gave the protected pentasaccharide **26** in 67% yield.




Fig. 9. Synthesis of **20**, **22**, **24**, and **26**. a. NIS, TfOH, MS 4Å, CH₂Cl₂, 0 °C, 9 h, 62%;

b. NIS, TfOH, MS 4Å, CH₂Cl₂, 0 °C, 11 h, 68%; c. NIS, TfOH, MS 4Å, CH₂Cl₂, -20

°C, 3 h, 60%; d. NIS, TBDMSOTf, MS 4Å, CH₂Cl₂, 0 °C, 8 h, 67%.




Fig. 10. Global deprotection of **2**, **5**, **20**, **22**, **24**, and **26**. a. (i) LiOH · H₂O, Dioxane, H₂O, 90-95 °C, 36 h; (ii) Ac₂O, NaHCO₃, H₂O then LiOH, H₂O, rt, 12 h; (iii) Pd(OH)₂, H₂, CH₃OH, H₂O, rt, 12 h; b. (i) LiOH · H₂O, Dioxane, H₂O, 90-95 °C, 36

1
2
3 h; (ii) Ac₂O, pyridine, DMAP, 12 h; (iii) BF₃.OEt₂, CH₃CN, 0 °C→rt, 18 h; (iv) LiOH,
4
5 H₂O, rt, 12 h (v) Pd(OH)₂, H₂, CH₃OH, H₂O, rt, 12 h.
6
7
8
9

10 Global deprotection of the protected hexasaccharide **2** and pentasaccharide **26**
11 was achieved using a four-step procedure: (i) hydrolysis of acyl protecting groups; (ii)
12 acetylation of the amine groups; (iii) removal of the acetonide groups; and (iv)
13 hydrogenolysis of the resulting benzyl ethers to provide the fully deprotected
14 hexasaccharide **1** and pentasaccharide **31**. In addition, using a similar strategy,
15 deprotection of **5**, **20**, **22**, and **24** gave the corresponding deprotected oligosaccharides
16 **27-30**, respectively, in good yields. These materials can be used for the preparation of
17 a glycan array for antibody binding study and for the preparation of glycoconjugates
18 for vaccine development.
19
20
21
22
23
24
25
26
27
28

29 To confirm that the synthesized hexasaccharide **1** was indeed the RM2 antigen and
30 to further understand the antibody binding specificity, we prepared an expanded
31 glycan array containing the synthesized hexasaccharide **1** and its analogs along with
32 the other ninety glycans prepared in our laboratory to form a glycan array for testing
33 (Fig. S4). All glycans were directly immobilized onto NHS-coated glass slides by
34 taking an aliquot from a stock solution of sugar at a fixed concentration (100 μM).
35 The assay involved an initial treatment with RM2 (a mouse IgM anti-RM2
36 monoclonal antibody, a kind gift from Prof. Saito), followed by incubation with a
37 fluorescein-tagged anti mouse IgM secondary antibody against its primary antibody.
38 After one hour incubation, the slides were washed with ddH₂O twice and scanned to
39 show the binding specificity of the antibody to printed oligosaccharides. The resulted
40 images showed that monoclonal RM2 antibody recognize hexasaccharide **1**
41 specifically, indicating that the synthetic hexasaccharide **1** contains the same antigenic
42 epitope with which RM2 antibody reacts on prostate cancer cells (Fig. 11); therefore,
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

we concluded that the synthesized hexasaccharide **1** was indeed the RM2 antigen. Moreover, the structure assignment of the synthesized hexasaccharide **1** is confirmed by both 1D and 2D-NMR (Fig. S1 and Table S2). Furthermore, to determine the dissociation constants of RM2 and truncated analogs on the surface interacting with the antibody in a multivalent manner, we followed the direct measurement method developed in our laboratory,³⁹ using different concentrations of antibodies and printed sugars. The results showed that when the printing concentration is below 6.25 μM , the average distance between printed sugars is too far to have enough multivalent effect with antibody RM2. At the printing concentrations from 100 μM to 6.25 μM , however, we observed that the $K_{D,\text{surf}}$ values measured were narrowly distributed from the individual curves (Fig. S2 and Table S3). Using the same method, the $K_{D,\text{surf}}$ values were determined for the truncated RM2 analog **29** interacting with the antibody (Fig. S3 and Table S4). Overall, the relative binding specificity of RM2 for the epitopes was RM2 > pentasaccharide **29** (Table 1).




Fig. 11. Binding specificity of monoclonal antibodies RM2 to RM2 antigen and its fragments.

Table 1. $K_{D,surf}$ (nM) values of different antibodies and different RM2 analogs.

Antibody	$K_{D,surf}$ (nM) \pm SD(nM)	
	RM2 (1)	Pentasaccharide, 29
RM2	4.545 \pm 0.903	5.756 \pm 1.140

Synthesis of DT-RM_{4,7} as a vaccine candidate with glycolipid C34 as adjuvant.

To develop a general protocol⁴⁰ for carbohydrate-carrier protein conjugation (Fig. 12 and Table S5), we adopted the thiol-maleimide coupling method for sialic acid-rich compounds. The amine group of the hexasaccharide **1** was reacted with 2 equiv of 3,3'-Dithiobis(sulfo-succinimidylpropionate) (DTSSP) and an amine-reactive *N*-hydroxysulfosuccinimide (sulfo-NHS) ester at each end of an 8-carbon spacer arm in pH 7.4 phosphate buffer at room temperature for 8 h to afford the corresponding half ester. Next, the disulfide bond was cleaved in the presence of dithiothreitol (DTT) at 40 °C for 2 h to obtain the free thio product **32** as Michael donors in 78% yield after purification on a size exclusion column LH-20. Furthermore, in order to generate the thio active maleimide group on the protein, CRM197 was reacted with an excess of *N*-(ϵ -Maleimidocaproyloxy) sulfosuccinimide ester (Sulfo-EMCS) in pH 7.0 phosphate buffer for 2 h. The number of maleimide-linker on the protein was determined by MALDI-TOF mass spectrometer. In average, 12.85 molecules of maleimide linkers were coupled on each molecule of diphtheria toxin mutant CRM197. Finally, for protein conjugation, the purified thiolated hexasaccharide **32** was incubated with the derivatized protein in pH 7.2 phosphate buffer for 2 h at room temperature to obtain the RM2 antigen-CRM197 glycoconjugate which was shown to contain 4.7 molecules of RM2 antigen per

1
2
3 molecule of CRM197 (DT-RM_{4.7}) (Table S3). Our previous report showed that the
4 glyco-conjugate vaccine exhibited a better immunization result to induce a higher IgG
5 titer antibodies when combined with the α -galactosylceramide analogue C34 as an
6 adjuvant.³⁰ To study the effect of adjuvant on Ab response, groups of BALB/c mice
7 were immunized intramuscularly with 2 μ g of DT-RM_{4.7} in combination with 2 μ g of
8 α -galactosylceramide C1, its analogue C34,⁴⁰ or Alu (Fig. 13). Three vaccinations
9 were given at two-week intervals. Two weeks after the third injection, sera were
10 collected and subsequently tested with the previously mentioned glycan microarray
11 (96 glycans) (Fig. S5) to estimate the level and diversity of anti-RM2 related antibody.
12 The results showed that mouse anti-RM2 IgG titers increased as vaccination
13 proceeded and peaked after the third vaccination. Among the DT-RM_{4.7} vaccinated
14 groups, we found that DT-RM_{4.7}/C34 induced higher levels of anti-RM2 IgG titers
15 than DT-RM_{4.7}/C1 and DT-RM_{4.7}/Alu after dilution to 12,000-fold (Fig. 13).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31




Fig. 12. Scheme for producing synthetic candidate carbohydrate-based vaccine.




Fig. 13. Female BALB/c mice were immunized with 2 μ g of RM2 antigen of DT-RM_{4.7} in combination with 2 μ g of C1, C34, or Alu. Mouse serum was collected two weeks after the final immunization, and the production of IgG against RM2 antigen and its truncated analogs after dilution to 12,000-fold. Data represent as total fluorescence intensity of five mice \pm the SEM.

Search for the best epitope ratio of DT-RM vaccine adjuvanted with C34.

After indentifying C34 as the most effective adjuvant for DT-RM_{4.7}, we would like to determine the best epitope ratio of vaccine by changing the amount of RM2 antigen attached to each carrier protein DT (Fig. 13). Various equivalents of thiolated hexasaccharide **32** and different protein concentrations generally would generate diverse carbohydrate-protein ratios. The number of RM2 antigens on the protein was determined by MALDI-TOF mass spectrometer. After dialysis and analysis, we were able to conjugate, on average, 1.0, 3.0, 4.7, and 10 molecules of RM2 antigen to one molecule DT to give DT-RM_{1.0}, DT-RM_{3.0}, DT-RM_{4.7}, and DT-RM_{10.0} (Table S5).

1
2
3
4 Using the same vaccination protocol mentioned previously, sera were collected 2
5 weeks after the third vaccination, and the elicited Abs were subsequently profiled by a
6
7
8 RM2-coated glycan microarray. In general, we observed that when immunized with
9
10 DT-RM_{3,0} alone without adjuvant, mice generated only low titers of anti-RM2 IgG
11
12 (Fig. S4 A). The glycan microarray results showed that, on average, 4.7 RM2 antigens
13
14 conjugated to one DT induced the most abundant IgG titers against RM2 (Fig. 14 and
15
16 Fig. S4). Alternatively, when immunized with DT-RM_{3,0} alone without adjuvant, mice
17
18 generated only low titers of anti-RM2 IgG (Fig. S4 A). When we fixed the signal to
19
20 noise (S/N) ratio > 3, the induced IgG could be diluted to 12,000-fold before the
21
22 signal disappeared (Fig. S4 F). However, the induced IgM titer could only be diluted
23
24 to 60-fold (Fig. S4 E), and the IgM signals reached to the background after dilution to
25
26
27 200-fold.

28
29
30
31
32 Interestingly, the specificity analysis of the induced IgG antibodies by
33
34 DT-RM_{4,7}/C34 vaccine showed that the induced antibodies had a strong binding to the
35
36 RM2 antigen and weaker binding to its trisaccharide **27**, tetrasaccharide **28**,
37
38 pentasaccharide **29**, and pentasaccharide **30** (Fig. 14). We observed that these
39
40 oligosaccharides all contain the same epitope trisaccharide **27** (NeuAc α 2→
41
42 6GlcNAc β 1→3Gal β 1→R). To further evaluate the vaccine specificity, we constructed
43
44 a glycan microarray created by STn, DSGG, RM2 antigen, RM2 antigen analogs, and
45
46 RM2 antigen fragments (Fig. 15). In general, specificity analysis of the induced
47
48 antibodies by DT-RM_{4,7}/C34 vaccine showed that the induced antibodies mainly
49
50 bound to the RM2 antigen and to its trisaccharide epitope **27**, a lesser extent to
51
52 disaccharide **32** (NeuAc α 2→6GlcNAc β 1→R) and trisaccharide **33** (NeuAc α 2→
53
54 6GlcNAc β 1→3Glu β 1→R). Besides, there is no detectable signal of binding to
55
56 NeuAc 2→6Gal, DSGG, or STn.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

It was reported that DT could induce antigen-specific T cell proliferation and elevate splenocytes production of IL-2, IFN- γ , and IL-6, suggesting their role in the Th1 driven pathway.⁴¹⁻⁴³ Furthermore, the glycolipid C34 was able to induce higher production of IFN- γ and IL-4, indicating a more Th1-skewed antigen.⁴⁴ But, the induced subtypes anti- DT-RM_{4,7}/C34 antibodies were mainly IgG1 antibodies with a trace amount of IgG2b and IgG2c antibodies and no detectable IgG2a (Fig. 16).

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Complement-dependent cytotoxicity (CDC) is one of the most potent cell killing mechanisms mediating the immune response in which IgG or IgM antibodies bind to antigens on the tumor or cancer cell surface. Complement activation, initiated through complement protein C1q binding to the Fc region of the IgM or IgG isotype antibodies, represents the important activity of antibodies against circulating tumor cells and micrometastases. To evaluate the therapeutic potential of anti-RM2 antibodies, we tested the complement-dependent cytotoxicity with prostate cancer cell line LNCap in the presence of new born rabbit complement. The ability of antibodies to induce complement activation is strongly dependent on the antibody isotype and epitope recognized. Thus, isotype IgG1 and IgG3 are able to activate the complement cascade particularly well through C1q, in contrast to IgG2 and IgG4⁴⁵. As shown above, our vaccine formulation resulted in a higher titer of subclass IgG1 antibodies than other subclasses, and the immune serum showed a strong complement-mediated cytotoxicity activity on the RM2-positive human prostate cancer cell line LNCap (Fig. 17). These data suggested that our carbohydrate-based vaccine DT-RM, based on the chemically synthetic hexaccharide **1** and a mutated diphtheria toxin (DT) with adjuvant C34 may create an efficient immune stimulation in human.




Fig. 14. The induced IgG titers against RM2 antigen and glycan binding profile of IgG collected from different epitope ratios of DT-RM/C34-immunized mice.




Fig. 15. Specificity analysis of the induced antibodies by DT-RM_{4.7}/C34 vaccine.




Fig. 16. The glycan binding profiles of induced IgG subtypes titers collected from DT-RM_{4.7}/C34-immunized mice two weeks after the third injection.




Fig. 17. CDC activity of the induced antibodies by serum from vaccination mice in the presence of rabbit complement. Lysis of human prostate cancer cell line LNCap at different concentrations.

Conclusion

In conclusion, we have successfully synthesized the prostate tumor carbohydrate RM2 antigen and its analogs as single stereoisomers in every glycosylation step in good yields. We used these synthetic glycans combined with other related glycans to

1
2
3
4 form a 96-member glycan microarray to study the specificity of monoclonal RM2
5
6 antibody and confirmed the structure of our synthetic RM2 hexasaccharide antigen.
7
8 Moreover, the synthesized RM2 carbohydrate antigen was incorporated into the
9
10 carrier protein CRM197 in an average number of 1~10. After vaccination studies in
11
12 mice, we used the glycan microarray to monitor their immune response. Our results
13
14 indicated that when one molecule of DT was conjugated with 4.7 molecules of RM2
15
16 antigen in average (DT-RM_{4.7}) and adjuvanted with the glycolipid C34 exhibited the
17
18 strongest anti-RM2 antigen titer. More importantly, this oligosaccharide-protein
19
20 conjugates are TD antigens, and the induced IgG antibody titers were much higher
21
22 than IgM antibody titers. In IgG subclasses analysis, IgG1 antibody was predominant
23
24 in the serum, while IgG3, a typical anti-carbohydrate antibody, also present in high
25
26 level. In addition, the induced mouse antibodies mediated effective
27
28 complement-dependent cytotoxicity (CDC) against the prostate cancer cell line
29
30 LNCap.
31
32
33
34
35

36 **Supporting Information Available**

37
38 Supplementary schemes, synthetic methods, and experimental protocols. This
39
40 material is available free of charge via the Internet at <http://pubs.acs.org>.
41
42
43

44 **AUTHOR INFORMATION**

45 **Corresponding Author**

46
47
48 cyiwu@gate.sinica.edu.tw; chwong@gate.sinica.edu.tw
49
50
51

52 **Notes**

53
54
55 The authors declare no competing financial interest.
56
57
58
59
60

Acknowledgement

The authors thank Prof. Seiichi Saito in the University of the Ryukyus, Okinawa, Japan for his kindly provided RM2 antibody, and Dr. Kun-Hsien Lin for providing the adjuvant C34. This work was supported by Academia Sinica and National Science Council, Taiwan. (Grant # NSC-100-2325-B-001-015 and NSC-101-2325-B-001-014 to CYW).

References

- (1) Stevanovic, S. *Nat. Rev. Cancer*. **2002**, *2*, 514.
- (2) Hakomori, S.; Zhang, Y. M. *Chem. Biol.* **1997**, *4*, 97.
- (3) Freire, T.; Bay, S.; Vichier-Guerre, S.; Lo-Man, R.; Leclerc, C. *Mini-Rev. Med. Chem.* **2006**, *6*, 1357.
- (4) Dube, D. H.; Bertozzi, C. R. *Nat. Rev. Drug Discov.* **2005**, *4*, 477.
- (5) Ragupathi, G.; Park, T. K.; Zhang, S. L.; Kim, I. J.; Graber, L.; Adluri, S.; Lloyd, K. O.; Danishefsky, S. J.; Livingston, P. O. *Angew. Chem. Int. Edit.* **1997**, *36*, 125.
- (6) Park, T. K.; Kim, I. J.; Hu, S. H.; Bilodeau, M. T.; Randolph, J. T.; Kwon, O.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1996**, *118*, 11488.
- (7) Slovin, S. F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; Bornmann, W. G.; Fazzari, M.; Dantis, L.; Olkiewicz, K.; Lloyd, K. O.; Livingston, P. O.; Danishefsky, S. J.; Scher, H. I. *Proc. Nat. Acad. Sci. U. S. A.* **1999**, *96*, 5710.
- (8) Gilewski, T.; Ragupathi, G.; Bhuta, S.; Williams, L. J.; Musselli, C.; Zhang, X. F.; Bornmann, W. G.; Spassova, M.; Bencsath, K. P.; Panageas, K. S.; Chin, J.; Hudis, C. A.; Norton, L.; Houghton, A. N.; Livingston, P. O.; Danishefsky, S. J. *Proc. Nat. Acad. Sci. U. S. A.* **2001**, *98*, 3270.
- (9) Nagorny, P.; Kim, W. H.; Wan, Q.; Lee, D.; Danishefsky, S. J. *J. Org. Chem.* **2009**, *74*, 5157.
- (10) Dickler, M. N.; Ragupathi, G.; Liu, N. X.; Musselli, C.; Martino, D. J.; Miller, V. A.; Kris, M. G.; Brezicka, F. T.; Livingston, P. O.; Grant, S. C. *Clin. Cancer Res.* **1999**, *5*, 2773.
- (11) Sabbatini, P. J.; Kudryashov, V.; Ragupathi, G.; Danishefsky, S. J.; Livingston, P. O.; Bornmann, W.; Spassova, M.; Zatorski, A.; Spriggs, D.; Aghajanian, C.; Soignet, S.; Peyton, M.; O'Flaherty, C.; Curtin, J.; Lloyd, K. O. *Int. J. Cancer*

1
2
3 **2000**, 87, 79.

4 (12) Yamago, S.; Yamada, T.; Hara, O.; Ito, H.; Mino, Y.; Yoshida, J. *Org. Lett.*
5 **2001**, 3, 3867.

6 (13) Saito, S.; Murayama, Y.; Pan, Y.; Taima, T.; Fujimura, T.; Murayama, K.;
7 Sadilek, M.; Egawa, S.; Ueno, S.; Ito, A.; Ishidoaya, S.; Nakagawa, H.; Kato, M.;
8 Satoh, M.; Endoh, M.; Arai, Y. *Int. J. Cancer* **2008**, 123, 633.

9 (14) Saito, S.; Egawa, S.; Endoh, M.; Ueno, S.; Ito, A.; Numahata, K.; Satoh, M.;
10 Kuwao, S.; Baba, S.; Hakomori, S.; Arai, Y. *Int. J. Cancer* **2005**, 115, 105.

11 (15) Ito, A.; Saito, S.; Masuko, T.; Oh-eda, M.; Matsuura, T.; Satoh, M.; Nejad, F.
12 M.; Enomoto, T.; Orikasa, S.; Hakomori, S. *Glycoconjugate J.* **2001**, 18, 475.

13 (16) Fukushi, Y.; Nudelman, E.; Levery, S. B.; Higuchi, T.; Hakomori, S.
14 *Biochemistry-Us* **1986**, 25, 2859.

15 (17) Ito, A.; Handa, K.; Withers, D. A.; Satoh, M.; Hakomori, S. I. *FEBS Lett.*
16 **2001**, 504, 81.

17 (18) Ando, T.; Ishida, H.; Kiso, M. *Carbohydr. Res.* **2003**, 338, 503.

18 (19) Brown, D. A.; Kondo, K. L.; Wong, S. W.; Diamond, D. J. *Eur. J. Immunol.*
19 **1992**, 22, 2419.

20 (20) Marra, A.; Dong, X.; Petitou, M.; Sinay, P. *Carbohydr. Res.* **1989**, 195, 39.

21 (21) Haberman, J. M.; Gin, D. Y. *Org. Lett.* **2003**, 5, 2539.

22 (22) Lin, C. C.; Huang, K. T. *Org. Lett.* **2005**, 7, 4169.

23 (23) Ando, T.; Ishida, H.; Kiso, M. *Carbohydr. Res.* **2003**, 338, 503.

24 (24) Ando, H.; Koike, Y.; Koizumi, S.; Ishida, H.; Kiso, M. *Angew. Chem. Int.*
25 *Ed.* **2005**, 44, 6759.

26 (25) Crich, D.; Li, W. *J. Org. Chem.* **2007**, 72, 7794.

27 (26) Tanaka, H.; Nishiura, Y.; Takahashi, T. *J. Am. Chem. Soc.* **2006**, 128, 7124.

28 (27) Hsu, C. H.; Chu, K. C.; Lin, Y. S.; Han, J. L.; Peng, Y. S.; Ren, C. T.; Wu, C.
29 Y.; Wong, C. H. *Chem.-Eur. J.* **2010**, 16, 1754.

30 (28) Raghavan, S.; Kahne, D. *J. Am. Chem. Soc.* **1993**, 115, 1580.

31 (29) Hsu, C. H.; Hung, S. C.; Wu, C. Y.; Wong, C. H. *Angew. Chem. Int. Ed.*
32 **2011**, 50, 11872.

33 (30) Ley, S. V.; Priepke, H. W. M. *Angew. Chem. Int. Edit.* **1994**, 33, 2292.

34 (31) Ley, S. V.; Priepke, H. W. M.; Warriner, S. L. *Angew. Chem. Int. Edit.* **1994**,
35 33, 2290.

36 (32) Crich, D.; Sun, S. X. *J. Am. Chem. Soc.* **1998**, 120, 435.

37 (33) Kanie, O.; Ito, Y.; Ogawa, T. *J. Am. Chem. Soc.* **1994**, 116, 12073.

38 (34) Komori, T.; Imamura, A.; Ando, H.; Ishida, H.; Kiso, M. *Carbohydr. Res.*
39 **2009**, 344, 1453.

40 (35) Huang, L. J.; Wang, Z.; Li, X. N.; Ye, X. S.; Huang, X. F. *Carbohydr. Res.*
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2006, 341, 1669.

(36) Wang, Z.; Zhou, L. Y.; El-Boubbou, K.; Ye, X. S.; Huang, X. F. *J. Org. Chem.* **2007**, 72, 6409.

(37) Tanaka, H.; Nishiura, Y.; Takahashi, T. *J. Am. Chem. Soc.* **2008**, 130, 17244.

(38) Lu, G. K.; Wang, P.; Liu, Q. C.; Zhang, Z. H.; Zhang, W.; Li, Y. X. *Chin. J. Chem.* **2009**, 27, 2217.

(39) Liang, P. H.; Wang, S. K.; Wong, C. H. *J. Am. Chem. Soc.* **2007**, 129, 11177.

(40) Huang, Y. L.; Hung, J. T.; Cheung, S. K.; Lee, H. Y.; Chu, K. C.; Li, S. T.; Lin, Y. C.; Ren, C. T.; Cheng, T. J.; Hsu, T. L.; Yu, A. L.; Wu, C. Y.; Wong, C. H. *Proc. Nat. Acad. Sci. U. S. A.* **2013**, 110, 2517.

(41) Miyaji, E. N.; Mazzantini, R. P.; Dias, W. O.; Nascimento, A. L.; Marcovistz, R.; Matos, D. S.; Raw, I.; Winter, N.; Gicquel, B.; Rappuoli, R.; Leite, L. C. *Infect. Immun.* **2001**, 69, 869.

(42) Godefroy, S.; Peyre, A.; Garcia, N.; Muller, S.; Sesardic, D.; Partidos, C. D. *Infect. Immun.* **2005**, 73, 4803.

(43) Stickings, P.; Peyre, M.; Coombes, L.; Muller, S.; Rappuoli, R.; Del Giudice, G.; Partidos, C. D.; Sesardic, D. *Infect. Immun.* **2008**, 76, 1766.

(44) Wu, T. N.; Lin, K. H.; Chang, Y. J.; Huang, J. R.; Cheng, J. Y.; Yu, A. L.; Wong, C. H. *Proceedings of the Proc. Nat. Acad. Sci. U. S. A.* **2011**, 108, 17275.

(45) Cooper, N. R. *Adv. Immunol.* **1985**, 37, 151.

Table of Content

